Form 4: Medifast Director Scott Schlackman Receives 11,168 Restricted Stock Units

Medifast Inc. Director Scott Schlackman was granted 11,168 restricted stock units as part of his annual director fees, vesting fully on June 25, 2026.

Summary

• Scott Schlackman, a Director of Medifast Inc. (MED), acquired 11,168 shares of common stock on June 25, 2025.
• These shares were granted as Restricted Stock Units (RSUs) with a price of $0 per share, indicating a grant rather than a purchase.
• The grant was made under the Medifast, Inc. Director's Deferred Compensation Plan, as Amended and Restated, and sourced from the Issuer's Amended and Restated 2012 Share Incentive Plan.
• The 11,168 RSUs are scheduled to vest in full on June 25, 2026.
• Following this transaction, Mr. Schlackman beneficially owns a total of 25,548.707 shares of Medifast common stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates standard corporate governance practices and aligns director interests with shareholders, with minimal negative impact from dilution.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Scott Schlackman aligns his interests with those of shareholders, as the value of his compensation is directly tied to the company's stock performance.
• This transaction is part of a structured Director's Deferred Compensation Plan, indicating a standard and transparent approach to executive and director remuneration.

Negatives

• The issuance of new shares for RSU grants can lead to minor dilution for existing shareholders, although the impact from this specific grant of 11,168 shares is likely minimal.

Future Outlook

The 11,168 restricted stock units granted to Director Scott Schlackman are scheduled to vest in full on June 25, 2026, indicating a future milestone for this compensation.

Industry Context

The granting of restricted stock units (RSUs) to directors is a common practice across various industries, including the health and wellness sector where Medifast operates. This method of compensation is widely used to attract and retain talent, and to align the interests of directors with long-term shareholder value.

Comparison to Industry Standards

• This Form 4 details a standard RSU grant to a director, a common practice in corporate compensation structures.
• The use of RSUs for director compensation is a widely accepted and transparent method, consistent with practices seen in many publicly traded companies across various sectors.
• While specific comparable companies or projects are not mentioned in this filing, the number of units granted would typically be benchmarked against peer companies of similar size and industry.

Corporate Governance

Related Party Transactions

• The grant of 11,168 restricted stock units to Scott Schlackman, a Director of Medifast Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: Experience minor dilution due to the issuance of new shares for the RSU grant, but benefit from increased alignment of the director's interests with long-term company performance.

Next Steps

• The 11,168 restricted stock units granted to Director Scott Schlackman are scheduled to vest in full on June 25, 2026.

Key Dates

Keywords

Medifast, MED, Scott Schlackman, Form 4, SEC filing, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Corporate Governance